Dec 7, 2011 | Recent Deals | Silicon Valley
O’Melveny & Myers LLP represented Celsion Corporation, a leading oncology company dedicated to the development and commercialization of innovative cancer drugs, in the closing of a US$15 million private placement that includes commitments by leading life science institutional investors.
The O’Melveny team was led by Mergers & Acquisitions partners Sam Zucker and Paul Scrivano, counsel Jennifer DePalma, and associate Sri Venkatasamy.
Related Posts:
- O’Melveny Represents Celsion in Registered Direct Offering
- O’Melveny Represents Cytomx Therapeutics in Expansion of Series B Financing
- O’Melveny Represents Dicerna Pharmaceuticals in US$60 Million Private Financing Transaction
- O’Melveny Represents Progenics Pharmaceuticals in Proposed Public Offering
- O’Melveny Represents Alliance Health Networks in Acquisition of Medify
